Target modeling and compound screening services

Foldyne's groundbreaking thermodynamic docking technology enables succesful prediction of compound affinity where classical docking methods tend to fail. Even in the lead discovery process, where low-affinity compounds have to be identified, thermodynamic docking technology enriches your compound assay up to 90%. Upon request Foldyne screens a client specific target-compound system. Compounds are available from structural databases or will be designed on the basis of the active site within the target structure. To cover for genetic diversity of the patient population, target assays based on SNP's are applied.

Disease	Target structure	Target name
Cancer, inflammation		P38 mitogen-activated kinase
Cancer		Topoisomerase
Bowel cancer		Nuclear transcription factor NF-Kappa
Malaria		Dihydrofolate reductase (DHFR)
Tuberculosis		Peptide deformylase
Hepatoxicity		P450 Cytochrome
Aging		Dna repair hydrolase XPF
Rheumatoid arthritis		IGM antibody
Alzheimer's disease		B-Amyloid association

[ ]